Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine

NCT01492101 is registered in ClinicalTrials.gov with Nektar Therapeutics as lead sponsor.

NCT NCT01492101
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01492101 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Lead sponsor
Nektar Therapeutics
Phase
Phase 3
Overall status
Completed
Start date
December 31, 2011
Completion date
June 30, 2016
Enrollment
852 (actual)
Sites
153

Conditions

As the registry lists them; a condition with its own page is linked.

locally recurrent breast cancer, metastatic breast cancer